Targeted Drug Delivery Systems for Glioma Therapy

Glioma remains one of the most formidable central nervous system malignancies, owing to its diffuse infiltration, cellular heterogeneity and the restrictive blood–brain barrier (BBB). Conventional chemotherapy often fails to achieve therapeutic concentrations in the tumour bed and causes systemic toxicity. Targeted drug delivery systems address these challenges by combining nanoscale carriers with ligands that engage receptors overexpressed on glioma cells, neovasculature or tumour-associated macrophages. These carriers include liposomes, polymeric micelles, dendrimers and inorganic nanoparticles, many of which are engineered for stimulus-responsive release, dual-modal imaging or immunomodulation. Strategies such as protein corona manipulation harness endogenous proteins to mediate transcytosis, while alternative administration routes—convection-enhanced delivery and intranasal inoculation—bypass the BBB. By integrating therapeutic payloads with diagnostic tracers and ligands, these systems aim to enhance tumour specificity, overcome resistance mechanisms and personalise intervention for improved patient outcomes.

Research from Nature Portfolio

Recent studies have revealed that ligand-targeted liposomes can incur rapid clearance due to natural IgM adsorption. By designing a compact peptidomimetic ligand (D8), researchers attenuated IgM binding, thereby extending circulation time and preserving receptor affinity for brain endothelium. This advance highlights the importance of immunocompatibility in targeted nanocarriers. Foundational work on a poly(L-γ-glutamyl-glutamine)-paclitaxel conjugate further demonstrated a self-assembling nanoparticle that incorporates Gd-DTPA as an MRI contrast agent. These ~36 nm particles exhibited nearly fivefold enhanced relaxivity compared to free Gd-DTPA, accumulated in tumours via the enhanced permeability and retention effect and delivered paclitaxel with notable antitumour efficacy, illustrating a robust theranostic platform for glioma management.

Targeted Drug Delivery Systems for Glioma Therapy publication trend

The graph below shows the total number of articles in targeted drug delivery systems for glioma therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Blood–brain barrier (BBB): The physiological barrier formed by endothelial cells that restricts passage of substances from the bloodstream into the brain.

Protein corona: The layer of plasma proteins adsorbed on a nanoparticle’s surface, which determines its biological identity and fate.

Liposome: A nanoscale vesicle composed of lipid bilayers used to encapsulate drugs and enhance targeted delivery.

Peptidomimetic: A synthetic molecule designed to emulate the structure and function of a peptide with increased stability.

Theranostics: Systems that integrate diagnostic imaging and therapeutic delivery within a single nanoplatform.

Receptor-mediated transcytosis: A process by which molecules traverse endothelial barriers by binding specific cell-surface receptors.

References

1. Peptide-Hitchhiking for the Development of Nanosystems in Glioblastoma. ACS Nano (2024).
2. A Novel Blood–Brain Barrier-Penetrating and Vascular-Targeting Chimeric Peptide Inhibits Glioma Angiogenesis. International Journal of Molecular Sciences (2023).
3. Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption. Nature Communications (2018).
4. Novel brain-targeted nanomicelles for anti-glioma therapy mediated by the ApoE-enriched protein corona in vivo. Journal of Nanobiotechnology (2021).
5. A Novel Gd-DTPA-conjugated Poly(L-γ-glutamyl-glutamine)-paclitaxel Polymeric Delivery System for Tumor Theranostics. Scientific Reports (2017).